Heartseed (219A) · PolicyRestated
Using the conditional and time-limited approval system
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Use of the Conditional and Time-Limited Approval System for Regenerative Medicine ProductsA theme 3 companies write about · 0 as a headwind · 3 as a tailwind
0 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We continue to pursue our most important strategy of using the conditional and time-limited approval system wherever possible to achieve the early practical application of regenerative medicine products under development.」
The Company continues to pursue early practical application of regenerative medicine products by making maximum use of the conditional and time-limited approval system. - FY2024First statedAnnual report
「We continue to pursue our most important strategy of using the conditional and time-limited approval system wherever possible to achieve the early practical application of regenerative medicine products under development.」
The conditional and time-limited approval system is positioned as a key development policy for early practical application.